Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Two new St Jude Medical defibrillators receive US FDA approval

St Jude Medical : 09 May, 2007  (New Product)
The US Food and Drug Administration has approved St Jude Medical's newest devices for treating patients with potentially lethal heart conditions.
The Current ICD (implantable cardioverter defibrillator) and Promote CRT-D (cardiac resynchronisation therapy defibrillator) are St Jude Medical's first devices to be built on the company's new consolidated hardware and software platform to support implantable cardiac devices.

The next generation 'Unity' device platform will enable St Jude Medical to more quickly update all devices with new features and diagnostics, as they become available, because the basic framework for all of the devices will be the same.

In addition, the consolidated platform's expanded capabilities can support, in the future, more advanced algorithms and features for better patient management.

Furthermore, programming during device follow-up will be streamlined, as all software interfaces for new St Jude Medical pacemakers, ICDs and CRT devices and most nominal settings will be the same.

The Promote CRT-D offers flexibility in pacing choices by allowing physicians to select an additional LV lead pacing pulse configuration.
(A lead is a thin, insulated wire, connected to the heart tissue on one end and to the device on the other end.

It transmits electrical impulses to the heart, and information from the heart back to the implanted device, so physicians can use it for diagnoses.

LV leads are placed in the lower left chamber of the heart).

This flexibility of allowing selection of the LV pacing configuration provides for more options to allow for optimizing pacing without the need to manually reposition the lead.

In addition, the VIP (Ventricular Intrinsic Preference) algorithm (currently available in St Jude Medical's Victory and Zephyr pacemakers) is now available in the Current ICD and provides a delay in device stimulation of the lower chambers of the heart (ventricles) to allow the patient's own heart rhythm to prevail when possible.

The VIP technology is designed to provide device stimulation only when needed, which has been shown to be better for patients' overall heart health.

Both devices also feature new patient management tools, such as enhanced patient exercise monitoring that gives the physician information about patient activity levels.
Improved lead monitoring capabilities - including adding daily checks of each shock vector to those performed for pacing vectors - provide added patient safety.

In addition to new parameters and diagnostics, the Current ICD and Promote CRT-D include these proprietary technologies available in previous St Jude Medical high-voltage devices:

- DeFT Response technology - which is designed to help devices meet the needs of patients with high or varying defibrillation thresholds.

- SenseAbility technology - which is designed to optimise sensing to help protect against inappropriate shocks.

- QuickOpt Timing Cycle Optimization - A programmer based optimisation method for people with CRT-Ds and ICDs that helps physicians quickly program the device's timing cycles - in about 90 seconds - to help deliver optimal therapy to patients.

As demonstrated in clinical studies, the QuickOpt feature produces results that are comparable to echocardiography, the current gold standard, but is significantly less costly and time-consuming.

- Vibrating patient notifier - The industry's only notifier that gently vibrates to notify patients of critical changes in device performance instead of issuing the standard audio alert; this can be especially beneficial for people with hearing loss.

'Our newest devices build upon the strengths of previous devices by offering tailored therapy, crucial diagnostic information and additional safety', said Michael J Coyle, President of St Jude Medical's Cardiac Rhythm Management Division.

'They exemplify our commitment to providing high-quality products for physicians and patients'.

The Current ICD and the Promote CRT-D are two of more than 20 new cardiac rhythm management products being introduced this year by St Jude Medical.
The wireless versions of the Current ICD and the Promote CRT-D devices (with radiofrequency telemetry) have just received European CE Mark approval.
RF telemetry enables secure, remote communication between the implanted device and the programmers in a clinician's office.

Wireless communication occurs while the device is being implanted and when patients see physicians for follow-up visits, allowing for safer, more convenient care and device management.

The feature is currently under review and is pending US regulatory approval.
An ICD is a small device implanted in the chest to treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardias or ventricular fibrillation), which often lead to sudden cardiac death (SCD).

Nearly 1,000 people every day and more than 350,000 every year in the USA die from SCD.

An ICD delivers potentially life saving therapy from the device to the patient's heart through an insulated wire or lead.

Cardiac resynchronisation therapy - delivered in an ICD or a pacemaker - resynchronises the beating of the heart's lower chambers (ventricles), which often beat out of sync in heart failure patients.

Studies have shown that CRT can improve the quality of life for many patients with heart failure, a progressive condition in which the heart weakens and loses its ability to pump an adequate supply of blood.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo